Drug Development
Classification:
Company News
Release time:
2018-06-07
The generic drug "Ezetimibe" developed by our company received the clinical trial approval in November 2016.
The generic drug "Pitavastatin Calcium" developed by our company received the clinical trial approval in October 2016.
The generic drug "Capecitabine" developed by our company received the clinical trial approval in September 2016.
The generic drug "Hydrobromide Vortioxetine" developed by our company received the clinical trial approval in August 2016.
The generic drug "Citrate Tofacitinib" developed by our company received the clinical trial approval in August 2016.
The generic drug "Lenalidomide" developed by our company received the clinical trial approval in April 2016.
The generic drug "Avanafil" developed by our company received the clinical trial approval in March 2016.
The generic drug "Topotecan" developed by our company received the clinical trial approval in March 2016.
The generic drug "Amorolfine Hydrochloride" developed by our company received the clinical trial approval in February 2016.
The generic drug "Ulipristal Acetate" developed by our company received the clinical trial approval in January 2016.
The generic drug "Erlotinib Hydrochloride" developed by our company received the clinical trial approval in January 2016.
The generic drug "Vilazodone Hydrochloride" developed by our company received the clinical trial approval in January 2016.
The generic drug "Anlotinib" developed by our company received the clinical trial approval in January 2016.
Research and development, clinical trials, company, pharmaceuticals, approval, obtained, developed, drugs, 2016, tablets
Beijing Hope Pharmaceutical Co., Ltd.
